TBI 302

Drug Profile

TBI 302

Alternative Names: HRC 204; TBI-302

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hemosol BioPharma
  • Developer Therapure Biopharma
  • Class Antineoplastics; Deoxyribonucleosides; Drug conjugates; Haemoglobins; Nucleosides; Pyrimidine nucleosides
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hepatocellular carcinoma
  • No development reported Colorectal cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Colorectal-cancer in Canada (IV, Infusion)
  • 07 Apr 2016 Pharmacodynamics, pharmacokinetics and adverse events data from a preclinical study in Hepatocellular carcinoma presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 25 Mar 2015 US FDA approves IND application for TBI 302 in Hepatocellular carcinoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top